Member Info for HotChip

Covid HC studies are an 'extra' to this business, but not key. Projections for next year exclude CH, so not sure why there is fuss over Covid CH delays. Anything gained from these are a bonus, but the focus is on other CH studies.

It bothers me that you say there is never just an alternative to 'hold'. This is not the case. Just because you are down significantly, doesn't mean that you have no alternatives. Seek advice in my opinion.

My view is that this is going to 12-13p soon.

DYOR

The rest of the markets gaining in price - what one's are they then, as I can only see stagnation or the opposite?

Welcome to AIM trading, this is normal :)

Unsurprisingly, the same people that were lauding CF when the SP was high are doing the opposite now the SP is low. You couldn't make that up, it's so predictable. When it goes back up into 20s and 30s, which may not be for a while, the same critics will reverse their thinking (and comments) and make positive noises.....again :)

No way, not the same CB - director of Bezant :)

DYOR

You can sell, if that helps.

A bit harsh, I can't see that one being answered.

On the flip-side though:

"we have been unable to achieve the commercial traction on our high throughput COVID-19 test that we anticipated."

and then states:

"our second COVID-19 product, a Point-of-care solution, is expected to come to market approximately at the same time as AIHL with a set of very attractive performance features that we believe will be differentiated in the market and see significant demand."

If they couldn't manage to do anything with the first product, what makes them certain they will achieve anthing with the next product?

DYOR

Reducing losses from c.£20million to c.£0.7million cannot be a bad thing though...

MrIndia - probably best to take full responsibility for your investment decisions and not try to blame others. You decided to invest, you pushed the buy button, not anyone else as far as I can see :)

I tabled a question around lagging SP at the latest investormeetcompany presentation and this is also in the Q&A doc. Focus is on driving the business and not focused on SP as this will take care of itself. They or their institutional investors are not worried about SP. Suggest you take a look at these docs.

MHC are definitely NOT doing LFTs. They confirmed that in last week's investor call and there are absolutely no plans to do so.

An RNS about what exactly? Are we expecting something?

I have seen some chat on this board regarding the potential content of today's presentation i.e. will they be covering this and that, they need to be updating on x and y, what's the plan post-covid etc.

This is all good, but my view is the only way to ensure you get all the answers you want is to put questions forward in advance. I have tabled at least five questions around concerns I have - institutional investors, share price depression, objectives, home-testing kit competition, why should private investors put money in etc.

I am sure this is only scratching the surface; but if any of you want to make your views known, you should engage with the board rather than just leaving comments here.

Everyone, before it's too late :(

No.

AIM and the market in general has been dire the past two weeks, JLP no exception. Look around at all the negativity impacting the markets, too much t mention.

who's panicking? I'm certainly not and can' see any reason too. Fundamentals are what count.

Q1 2022 is the next key update i.e. spin offs and FY results I believe at end-March.

Until then, I expect to see a number of high-value contracts for respiratory diseases throughout this period which will maintain the SP between 18p and 24p imo.

For those that are patient, I think we will be rewarded. But as bamb mentions below, turn off. It is not worth checking the SP on this one too often, just wait for RNS's and review then which is what I will be doing.

DYOR